Coherus Biosciences (CHRS) PT Lowered to $15 at Maxim Group
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.38 -2.82%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy lowered the price target on Coherus Biosciences (NASDAQ: CHRS) to $15.00 (from $17.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- Dycom Industries (DY) PT Lowered to $375 at Raymond James
- Recruit Holdings Co., Ltd (6098:JP) (RCRUY) PT Raised to JPY21,500 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
